Literature DB >> 7957522

Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.

S E Fowles1, S K Pratt, J Laroche, W T Prince.   

Abstract

Famciclovir has been shown to have potent and selective activity against herpesviruses. The possibility of a pharmacokinetic interaction between the anti-viral agent, famciclovir and allopurinol has been investigated in twelve healthy male volunteers following a single oral dose of famciclovir (500 mg) in the presence and absence of steady-state levels of allopurinol (300 mg). Similarly, the pharmacokinetic profiles of allopurinol and oxypurinol prior to and following a single dose of famciclovir were compared. Mean values of Cmax, AUC and terminal-phase half-life for penciclovir following administration of famciclovir alone at 3.3 micrograms.ml-1, 8.8 micrograms.h.ml-1 and 2.1 h, respectively were unchanged by co-administration of allopurinol. Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively. No evidence of accumulation of the inactive precursor to penciclovir, BRL 42359, was noted as a result of co-administration of the two drugs. Mean steady-state Cmax, AUC and terminal-phase half-life values for allopurinol after co-administration of allopurinol with famciclovir also appeared unchanged from values obtained after dosing of allopurinol alone, at 2.12 micrograms.ml-1, 5.73 micrograms.h.ml-1 and 1.38 h, respectively. Mean Cmax and AUC values of the active metabolite of allopurinol, oxypurinol were 11.2 micrograms.ml-1 and 96.0 micrograms.h.ml-1, respectively, and these were also unaltered by co-administration of famciclovir with allopurinol, with values of 10.6 micrograms/ml and 89.8 micrograms.h/ml, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957522     DOI: 10.1007/BF00194405

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 2.  Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity.

Authors:  C Beedham
Journal:  Prog Med Chem       Date:  1987

3.  A comparison of the specificities of xanthine oxidase and aldehyde oxidase.

Authors:  T A Krenitsky; S M Neil; G B Elion; G H Hitchings
Journal:  Arch Biochem Biophys       Date:  1972-06       Impact factor: 4.013

4.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors:  R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

Authors:  R O Day; J Miners; D J Birkett; G G Graham; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  Azathioprine and allopurinol: a potentially dangerous combination.

Authors:  G Venkat Raman; V L Sharman; H A Lee
Journal:  J Intern Med       Date:  1990-07       Impact factor: 8.989

7.  Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].

Authors:  R A Vere Hodge; D Sutton; M R Boyd; M R Harnden; R L Jarvest
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Xanthine oxidase from human liver: purification and characterization.

Authors:  T A Krenitsky; T Spector; W W Hall
Journal:  Arch Biochem Biophys       Date:  1986-05-15       Impact factor: 4.013

Review 9.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

10.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

View more
  4 in total

Review 1.  Pharmacokinetics of new antiherpetic agents.

Authors:  P Rolan
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

2.  Correlating C-H bond cleavage with molybdenum reduction in xanthine oxidase.

Authors:  Martin L Kirk; Abebe Berhane
Journal:  Chem Biodivers       Date:  2012-09       Impact factor: 2.408

3.  Spectroscopic and electronic structure studies probing covalency contributions to C-H bond activation and transition-state stabilization in xanthine oxidase.

Authors:  Joseph Sempombe; Benjamin Stein; Martin L Kirk
Journal:  Inorg Chem       Date:  2011-10-05       Impact factor: 5.165

Review 4.  Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.

Authors:  C M Perry; A J Wagstaff
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.